Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients

Journal of Cancer - Australia
doi 10.7150/jca.20889
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ivyspring International Publisher

Related search

Tumor Endothelial ELTD1 as a Predictive Marker for Treatment of Renal Cancer Patients With Sunitinib

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Dynamic Changes of Live/Apoptotic Circulating Tumour Cells as Predictive Marker of Response to Sunitinib in Metastatic Renal Cancer

British Journal of Cancer
Cancer ResearchOncology
2012English

Sunitinib for Advanced Renal Cell Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Mp16-01 Clinical Implications of Sunitinib and N-Desethyl-Sunitinib Plasma Concentrations for Treatment Outcome in Metastatic Renal Cell Carcinoma Patients

Journal of Urology
Urology
2017English

FAK-Copy-Gain Is a Predictive Marker for Sensitivity to FAK Inhibition in Breast Cancer

Cancers
Cancer ResearchOncology
2019English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases

Clinical Genitourinary Cancer
OncologyUrology
2014English

Is BCL-2 a Predictive Marker of Neoadjuvant Chemotherapy Response in Patients With Urothelial Bladder Cancer Undergoing Radical Cystectomy?

Scandinavian Journal of Urology
UrologyNephrology
2019English

SPARC Is a Possible Predictive Marker for Albumin-Bound Paclitaxel in Non-Small-Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy